
In 2022, US skin doctors may get their hands on a new tool for treating patients with plaque psoriasis.
So hopes biotech company Dermavant Sciences, which, mid-year, will be submitting a new drug application to the US Food and Drug Administration (FDA) on the basis of the drug tapinarof's new phase III trial results.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app